SGN-CD33A is an antibody-drug conjugate (ADC) targeting CD33, a protein that is expressed on most acute myeloid leukemia (AML) cells. SGN-CD33A employs our newest proprietary ADC technology. This technology comprises a potent cell-killing agent called a pyrrolobenzodiazepine (PBD) dimer that works by a different mechanism than auristatins. The PBD dimer is stably linked to an antibody with our site-specific engineered cysteines, resulting in uniform drug-loading of two PBD dimers per antibody. We call this engineered antibody an EC-mAb.
SGN-CD33A is in two phase 1 clinical trials designed to assess its safety and anti-leukemia activity in AML as a single agent and in combination with other standard treatments.